Abstract
It is now established that a subgroup of non-Hodgkin's lymphoma (NHL) patients probably benefit from high-dose therapy (HDT). We therefore retrospectively analyzed survival of 126 consecutive patients with large cell lymphoma (LCL) and high–intermediate (HI) or high-risk (H) age-adjusted international prognostic index (Aa-IPI). They received either standard chemotherapy (CT) (66 patients), or HDT (60 patients). Distribution of the Aa-IPI scores showed no statistical significant difference between the two treatment groups. Complete response (CR) rate was 51% for the whole series, with 41% and 62% for the standard CT group and HDT group, respectively. With a median follow-up of 63 months (range, 16 to 159), the 5-year overall survival (OS) and event-free survival (EFS) for all patients was 52% and 43%, respectively. There was a statistical significant difference in terms of survival towards the HDT group: OS at 76% vs 31%, EFS at 64% vs 24%. Patients who achieved CR with front-line therapy had a 5-year OS at 70%, while it was 34% for patients who were not in CR. These results are comparable to those reported in the literature, and strongly suggest that both initial CR achievement and HDT as front-line treatment are predictive factors for prolonged survival of patients with poor-risk LCL. Bone Marrow Transplantation (2000) 25, 35–40.
Similar content being viewed by others
References
Harris NL, Jaffe ES, Stein H et al. A revised European American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392
Fisher RI, De Vita VT Jr, Johnson BL et al. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy Am J Med 1977 63: 177–182
Laurence J, Coleman M, Allen SL et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen Ann Intern Med 1982 97: 190–195
Klimo P, Connors JM . MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma Ann Intern Med 1985 102: 596–602
Shipp MA, Harrington DP, Klatt MM et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD Ann Intern Med 1986 104: 757–765
Fisher RI, Gaynor ER, Dahlberg S et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma New Engl J Med 1993 328: 1002–1006
The International Non-Hodgkin's Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin's lymphoma New Engl J Med 1993 329: 987–994
Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma. Updated results of the prospective study LNH 87–2 J Clin Oncol 1997 15: 1131–1137
Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma New Engl J Med 1997 336: 1290–1297
Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group J Clin Oncol 1998 16: 2796–2802
Coiffier B, Gisselbrecht C, Herbrecht R et al. LNH-84 regimen. A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma J Clin Oncol 1989 7: 1018–1026
Stoppa AM, Bouabdallah R, Chabannon C et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma J Clin Oncol 1997 15: 1722–1729
Armitage JO, Cheson BD . Interpretation of clinical trials in diffuse large-cell lymphoma J Clin Oncol 1988 6: 1335–1347
Shipp MA, Abeloff MD, Antman KH et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury J Clin Oncol 1999 17: 423–429
Reyes F, Lepage E, Morel P et al. Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (pts) with aggressive lymphoma: updated results of the randomized LNH93–3 study Blood 1998 90: (Suppl. 1) 594a
Kaiser U, Uebelacker I, Havemann K . on behalf of the German High Grade Lymphoma Study Group, Marburg, Germany High-dose chemotherapy with autologous stem cell transplantation in high grade NHL: first analysis of a randomized multicenter study Bone Marrow Transplant 1998 21: (Suppl. 1) S177
Haq R, Sawka CA, Franssen E, Berinstein NL . Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review J Clin Oncol 1994 12: 1074–1084
Verdonck LF, van Putten WL, Hagenbeek A et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma New Engl J Med 1995 332: 1045–1051
Martelli M, Vignetti M, Zinzani P et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatine, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study J Clin Oncol 1996 14: 534–542
Vitolo U, Cortellazzo S, Liberati AM et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma J Clin Oncol 1997 15: 491–498
Nademanee A, Molina A, O'Donnell MR et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate and high-grade lymphoma. International index high and high–intermediate risk group Blood 1997 90: 3844–3852
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bouabdallah, R., Coso, D., Costello, R. et al. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: a retrospective series on 126 patients from a single center. Bone Marrow Transplant 25, 35–40 (2000). https://doi.org/10.1038/sj.bmt.1702080
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702080
- Springer Nature Limited